Considering that therapeutic resistance is a major hurdle for clinical utilization of crizotinib, these promising findings suggest that ASP3026 could be used to overcome crizotinib resistance in NPM-ALK+ ALCL. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.